Success Metrics

Clinical Success Rate

90.7%

Based on 49 completed trials

Completion Rate

91%(49/54)

Active Trials

1(2%)

Results Posted

33%(16 trials)

Terminated

5(8%)

Phase Distribution

Ph phase_3

27%

Ph not_applicable

Ph phase_1

Ph early_phase_1

Ph phase_2

11%

Ph phase_4

34%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution52 total trials

Early Phase 1First-in-human

1(1.9%)

Phase 1Safety & dosage

4(7.7%)

Phase 2Efficacy & side effects

7(13.5%)

Phase 3Large-scale testing

17(32.7%)

Phase 4Post-market surveillance

21(40.4%)

N/ANon-phased studies

2(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.0%

49 of 57 finished

Non-Completion Rate

14.0%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(49)

Terminated(8)

Other(3)

Detailed Status

Completed49

Terminated5

Withdrawn3

unknown2

Enrolling by invitation1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

90.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (1.9%)

Phase 14 (7.7%)

Phase 27 (13.5%)

Phase 317 (32.7%)

Phase 421 (40.4%)

N/A2 (3.8%)

Trials by Status

completed4979%

enrolling_by_invitation12%

suspended12%

unknown23%

withdrawn35%

terminated58%

active_not_recruiting12%

Recent Activity

1 active trials

Showing 5 of 62

completedphase_3

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703

View all 62 trials

Clinical Trials (62)

Showing 20 of 62 trialsScroll for more

NCT05355337Phase 3

Pramipexole for Anhedonic Depression

Completed

NCT05825235Phase 3

Long-term Efficacy of Pramipexole in Anhedonic Depression

Completed

NCT05003648Phase 4

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Active Not Recruiting

NCT07382960

Pramipexole and the Risk of Serious Adverse Events

Completed

NCT04759703Phase 2

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Terminated

NCT06580041Phase 4

Precision Care for Major Depressive Disorder

Enrolling By Invitation

NCT05401019Phase 2

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Withdrawn

NCT00349310

Profile of Depressive Symptoms in Parkinsons Disease

Completed

NCT04249544Phase 1

Social Decision Making in Parkinson's Disease

Completed

NCT04936126Phase 4

Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Unknown

NCT04160520Phase 1

Pramipexole and Morphine for Renal Colic

Completed

NCT03430596Early Phase 1

a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics

Completed

NCT03817554Phase 4

Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Terminated

NCT03845387Phase 2

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Completed

NCT00991276Phase 3

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Completed

NCT03681509Not Applicable

Pramipexole and Emotional Processing

Completed

NCT02397837Phase 4

Targeting Cognition in Bipolar Disorder With Pramipexole

Completed

NCT02033369Phase 4

Imaging Dopamine Release in Depression

Completed

NCT01673724Phase 4

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Completed

NCT01066897Phase 4

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 62